SOLIGENIX, INC. Net Income (Loss) Available to Common Stockholders, Diluted
SOLIGENIX, INC. (SNGX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$7.15 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-15.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2018-03-15
- SOLIGENIX, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2017-12-31 was -$2.14M.
- SOLIGENIX, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2017-09-30 was -$963.09K.
- SOLIGENIX, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2017-06-30 was -$2.31M.
- SOLIGENIX, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2017-03-31 was -$1.73M.
- SOLIGENIX, INC. net income (loss) available to common stockholders, diluted for fiscal 2017 was -$7.15M.
- SOLIGENIX, INC. net income (loss) available to common stockholders, diluted for fiscal 2016 was -$4.79M.
- SOLIGENIX, INC. net income (loss) available to common stockholders, diluted for fiscal 2015 was -$7.83M.
- SOLIGENIX, INC. net income (loss) available to common stockholders, diluted for fiscal 2014 was -$10.14M, a 200.84% decline from fiscal 2013.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$3.10M derived: sum of 2 quarters · filed 2018-03-15 | -$5.41M derived: sum of 3 quarters · filed 2018-03-15 | -$7.15M 10-K · filed 2018-03-15 |
| 2017-09-30 | -$963.09K 10-Q · filed 2017-11-06 | -$3.27M derived: sum of 2 quarters · filed 2017-11-06 | -$5.01M 10-Q · filed 2017-11-06 | -$5.77M derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-06-30 | -$2.31M 10-Q · filed 2017-08-11 | -$4.05M 10-Q · filed 2017-08-11 | -$4.81M derived: sum of 3 quarters · filed 2018-03-15 | -$6.48M derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-03-31 | -$1.73M 10-Q · filed 2017-05-11 | -$2.50M derived: sum of 2 quarters · filed 2018-03-15 | -$4.17M derived: sum of 3 quarters · filed 2018-03-15 | -$4.79M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-12-31 | -$762.01K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$2.44M derived: sum of 2 quarters · filed 2018-03-15 | -$3.05M derived: sum of 3 quarters · filed 2018-03-15 | -$4.79M 10-K · filed 2018-03-15 |
| 2016-09-30 | -$1.67M 10-Q · filed 2017-11-06 | -$2.29M derived: sum of 2 quarters · filed 2017-11-06 | -$4.02M 10-Q · filed 2017-11-06 | -$6.26M derived: sum of 4 quarters · filed 2017-11-06 |
| 2016-06-30 | -$618.10K 10-Q · filed 2017-08-11 | -$2.53M 10-Q · filed 2017-08-11 | -$4.59M derived: sum of 3 quarters · filed 2017-08-11 | -$5.86M derived: sum of 4 quarters · filed 2017-08-11 |
| 2016-03-31 | -$1.91M 10-Q · filed 2017-05-11 | -$3.97M derived: sum of 2 quarters · filed 2017-05-11 | -$5.24M derived: sum of 3 quarters · filed 2017-05-11 | -$9.22M derived: sum of 4 quarters · filed 2017-05-11 |
| 2015-12-31 | -$2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-27 | -$3.33M derived: sum of 2 quarters · filed 2017-03-27 | -$7.31M derived: sum of 3 quarters · filed 2017-03-27 | -$7.83M 10-K · filed 2017-03-27 |
| 2015-09-30 | -$1.27M 10-Q · filed 2016-11-10 | -$5.25M derived: sum of 2 quarters · filed 2016-11-10 | -$5.77M 10-Q · filed 2016-11-10 | -$11.33M derived: sum of 4 quarters · filed 2016-11-10 |
| 2015-06-30 | -$3.98M 10-Q · filed 2016-08-11 | -$8.55M 10-Q · filed 2016-08-11 | -$10.06M derived: sum of 3 quarters · filed 2016-08-11 | -$14.41M derived: sum of 4 quarters · filed 2016-08-11 |
| 2015-03-31 | -$4.57M 10-Q · filed 2016-05-12 | -$6.08M derived: sum of 2 quarters · filed 2016-05-12 | -$10.43M derived: sum of 3 quarters · filed 2016-05-12 | |
| 2014-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-24 | -$5.86M derived: sum of 2 quarters · filed 2016-03-24 | -$10.14M 10-K · filed 2016-03-24 | |
| 2014-09-30 | -$4.35M 10-Q · filed 2015-11-12 | -$8.63M 10-Q · filed 2015-11-12 | ||
| 2013-12-31 | $10.06M 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |